Seaport Therapeutics, Inc.
No enriched coverage for $SPTX in the last 7 days.
No SEC Form 4 filings for $SPTX in the last 30 days.
See all $SPTX insider activity →Seaport Therapeutics (SPTX) reported positive Phase 1 trial results for GlyphAllo, showing no next-morning driving impairment in healthy volunteers. The trial met primary and secondary endpoints, with GlyphAllo well-tolerated. The company plans to submit results to the FDA and present further data. SPTX stock closed at $24.06, up 3.95% in pre-market trading.
UBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
Recent SPTX coverage spans technology, earnings and financial news.
Positive early‑stage data may boost investor confidence and support upcoming Phase 2b readout.
Buy rating may attract buyers.
IPO proceeds and trial timeline drive strong buying interest.
IPO provides capital but no immediate catalyst; price may remain volatile.
Clinical and funding runway updates increase visibility into near-term catalysts for SPTX’s lead programs, especially GlyphAllo BUOY-1 topline timing and GlyphAgo advancement.
AlphAI scores every news story that mentions SPTX with an AI model for sentiment and relevance, and aggregates insider trades from Seaport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Seaport Therapeutics (SPTX) reported positive Phase 1 trial results for GlyphAllo, showing no next-morning driving impairment in healthy volunteers. The trial met primary and secondary endpoints, with GlyphAllo well-tolerated. The company plans to submit results to the FDA and present further data. SPTX stock closed at $24.06, up 3.95% in pre-market trading.
2 min readUBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
2 min readFive biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
3 min readSeaport Therapeutics (SPTX) debuted on NASDAQ in August 2026 with a $1.4B market cap, following a $260M IPO. Its GlyphAllo asset is in Phase 2b trials for MDD, with results expected in 1H 2027. Bristol Myers (BMY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Sanofi (SNY) are potential acquirers. SPTX has $427.26M in cash, a Q2 2026 net loss of $62.60M, and a runway into 2029.
2 min readSeaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 d
6 min readHOMBACH ROBERT J. purchased 13,000 indirectly-held shares of Seaport Therapeutics, Inc. (SPTX) at $18.14 ($0.24M total) on 2026-06-22.
2 min readPureTech’s founded entity Seaport Therapeutics reported positive Phase 1 multiple-ascending dose data for GlyphAgo (SPT-320) in healthy volunteers. Seaport said seven-day repeat dosing showed favorable safety/tolerability and PK consistent with prior single-dose results, with no liver-related adverse events and dose-dependent agomelatine exposure. Seaport plans Phase 2a in H2 2026 (topline early 2028) and Phase 2b in H1 2027 (topline by end-2028).
6 min readSeaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sptx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demons
6 min read
